Sector
PharmaceuticalsOpen
₹128.44Prev. Close
₹128.44Turnover(Lac.)
₹6.59Day's High
₹132.95Day's Low
₹122.0152 Week's High
₹198.8652 Week's Low
₹73.25Book Value
₹39.52Face Value
₹10Mkt Cap (₹ Cr.)
385.8P/E
213.33EPS
0.6Divi. Yield
019 Dec 2024
12:00 AM
EGM
18 Jul 2023
12:00 AM
Rights
2 Sep 2024
12:00 AM
AGM
Announcement Date: 02 Sep, 2024
2 Sep 2024
12:00 AM
BookCloser
10 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 26.25 | 24.7 | 24.7 | 24.7 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 43.28 | 32.08 | 40.3 | 39.51 |
Net Worth | 69.53 | 56.78 | 65 | 64.21 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 77.24 | 69.68 | 55.71 | 57.53 |
yoy growth (%) | 10.84 | 25.08 | -3.17 | -28.08 |
Raw materials | -47.47 | -46.82 | -39.37 | -36.66 |
As % of sales | 61.45 | 67.19 | 70.67 | 63.71 |
Employee costs | -14.36 | -13.38 | -11.8 | -8.25 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -8.43 | -13.51 | -17.53 | 2.48 |
Depreciation | -7.09 | -6.64 | -6.44 | -1.67 |
Tax paid | -7.15 | -10.86 | 3.72 | -0.81 |
Working capital | -1.12 | 6.26 | 0.96 | -6.78 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.84 | 25.08 | -3.17 | -28.08 |
Op profit growth | -119.47 | -55.87 | -276.31 | -54.51 |
EBIT growth | -47.44 | -32.66 | -532.2 | -69.59 |
Net profit growth | -36.05 | 76.47 | -928.65 | -84.32 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Gross Sales | 79.49 | 63.2 | 91.08 | 77.25 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 79.49 | 63.2 | 91.08 | 77.25 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.96 | 0.57 | 0.91 | 0.74 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.8 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,025.5 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,480 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,141.2 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,408.2 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director
Jitendra Pratap Singh
Whole-time Director
Durga Sankar Maity
Whole-time Director
Mr. Bhushan Singh Rana
Independent Director
Lalit Mahajan
Independent Director
Usha Singh
Independent Director
Manav Mahajan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Brooks Laboratories Ltd
Summary
Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. Brooks Laboratories is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, A
Read More
What is the Brooks Laboratories Ltd share price today?
The Brooks Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹130.97 today.
What is the Market Cap of Brooks Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Brooks Laboratories Ltd is ₹385.80 Cr. as of 09 May ‘25
What is the PE and PB ratio of Brooks Laboratories Ltd?
The PE and PB ratios of Brooks Laboratories Ltd is 213.33 and 3.26 as of 09 May ‘25
What is the 52 Week High and Low of Brooks Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Brooks Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Brooks Laboratories Ltd is ₹73.25 and ₹198.86 as of 09 May ‘25
What is the CAGR of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's CAGR for 5 Years at 31.36%, 3 Years at 15.75%, 1 Year at 24.70%, 6 Month at -8.03%, 3 Month at -17.16% and 1 Month at 3.91%.
What is the shareholding pattern of Brooks Laboratories Ltd?
The shareholding pattern of Brooks Laboratories Ltd is as follows:
Promoters - 52.62 %
Institutions - 10.43 %
Public - 36.95 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
